Skip to main content
SpringerLink
Log in

Taxane Formulations: From Plant to Clinic

  • Chapter
  • First Online:
Micro and Nanomanufacturing Volume II

Abstract

Taxanes including paclitaxel and docetaxel are highly active against many types of cancers. The main obstacle with developing delivery systems of taxanes is their poor water solubility. In this chapter, taxanes were reviewed in terms of their pharmacology, solubility and stability using traditional formulations such as those based on using Cremophor EL and novel nanocarrier-based formulations including liposome, nanoparticle and polymeric micelle delivery systems. Commercially available formulations of paclitaxel such as Taxol, Abraxane and Genexol-PM were highlighted.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Zhang A, Anyarambhatla L, Ma G, Ugwu L, Xuan S, Sardone T, Ahmed T, I. (2004) Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm 59:177–187

    Article  Google Scholar 

  2. Vaishampayan U, Parchment ER, Bhaskara JR, Maha H (1999) Taxanes: an overview of the pharmacokinetics and pharmacodynamics. Urology 54(6):122–129

    Article  Google Scholar 

  3. Thiesen J, Krämer I (1999) Physico-chemical stability of docetaxel premix solution and docetaxel infusion solutions in PVC bags and polyolefine containers. Pharm World Sci 21(3):137–141

    Article  Google Scholar 

  4. Verweij J, Clavel M, Chevalier B (1994) Paclitaxel and docetaxel: not simply two of a kind. Ann Oncol 5:495–505

    Article  Google Scholar 

  5. Jordan AM, Toso JR, Thrower D, Wilson L (1993) Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 90:9552–9556

    Article  Google Scholar 

  6. DeVita VT, Lawrence TS, Rosenberg SA, Weinberg RA, DePinho RA (2008) DeVita, Hellman, and Rosenberg’s cancer: principles & practice of oncology, vol 1. Lippincott Williams and Wilkins, Philadelphia, pp 447–450

    Google Scholar 

  7. Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277:665–667

    Article  Google Scholar 

  8. Rowinsky EK, Cazenave LA, Donehover RC (1990) Taxol: a novel investigational microtubule agent. J. Natl. Cancer Inst. 82:1247–1259

    Article  Google Scholar 

  9. Singla AK, Garg A, Aggarwal D (2002) Paclitaxel and its formulations. Int J Pharm 235:179–192

    Article  Google Scholar 

  10. O’Connell CB, Khodjakov AL (2007) Cooperative mechanisms of mitotic spindle formation. J Cell Sci 120:1717–1722

    Article  Google Scholar 

  11. Crown J, O’Leary M (2000) Taxanes an update. Lancet 355:1176–1178

    Article  Google Scholar 

  12. Kaye S, Piccart JM, Gore M, Huinink BTW, Oosterom VA, Verweij J, Wanders J, Franklin H, Bayssas M (1995) Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 87(9):676–681

    Article  Google Scholar 

  13. Engblom P, Pulkkinen OJ, Rantanen V, Hirvonen H, Kulmala J, Grènman R, Grènman S (1999) Effects of paclitaxel with or without cremophor EL on cellular clonogenic survival and apoptosis. Eur J Cancer 35(2):284–288

    Article  Google Scholar 

  14. Nuijen B, Bouma M, Schellens JHM, Beijnen JH (2001) Progress in the development of alternative pharmaceutical formulations of taxanes. Invest New Drugs 19(2):143–153

    Article  Google Scholar 

  15. Immordino ML, Brusa P, Arpicco S, Stella B, Dosio F, Cattel L (2003) Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J Control Release 91:417–429

    Article  Google Scholar 

  16. Engels FK, Mathot RAA, Verweij J (2007) Alternative drug formulations of docetaxel: a review. Anticancer Drugs 18:95–103

    Article  Google Scholar 

  17. Kattige A (2006) Long-term physical and chemical stability of a generic paclitaxel infusion under simulated storage and clinical-use conditions. Eur J Hosp Pharm Sci 12(6):129–134

    Google Scholar 

  18. Eroles AA, Bafalluy IM, Arnaiz JAS (2009) Stability of docetaxel diluted to 0.3 or 0.9 mg/mL with 0.9% sodium chloride injection and stored in polyolefin or glass containers. Am J Health Syst Pharm 66(17):1565–1568

    Article  Google Scholar 

  19. Donyai P, Sewell GJ (2006) Physical and chemical stability of paclitaxel infusions in different container types. J Oncol Pharm Pract 12(4):211–222

    Article  Google Scholar 

  20. Pourro B, Botta C, Solas C, Lacarelle B, Braguer D (2005) Seventy-two-hour stability of Taxol® in 5% dextrose or 0·9% sodium chloride in Viaflo®, Freeflex®, Ecoflac® and Macoflex N® non-PVC bags. J Clin Pharm Ther 30(5):455–458

    Article  Google Scholar 

  21. Trissel LA, Xu QA, Gilbert DL (1998) Compatibility and stability of paclitaxel combined with doxorubicin hydrochloride in infusion solutions. Ann Parmacother 32(10):1013–1016

    Article  Google Scholar 

  22. Dordunoo SK, Burt HM (1996) Solubility and stability of taxol: effects of buffers and cyclodextrins. Int J Pharm 133(1–2):191–201

    Article  Google Scholar 

  23. Waugh WN, Trissel LA, Stella VJ (1991) Stability, compatibility, and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers. Am J Hosp Pharm 48(7):1520–1524

    Google Scholar 

  24. Murphy SR, Wadey BL (1988) DEHP and toxicity. J Vinyl Technol 10(3):121–124

    Article  Google Scholar 

  25. Dorr RT (1994) Pharmacology and toxicology of Cremophor EL diluent. Ann Pharmacother 28:511–514

    Article  Google Scholar 

  26. Lilley LL, Scott HB (1993) What you need to know about taxol? Am. J. Nurs. 93:46–50

    Google Scholar 

  27. Gelderblom H, Verweij J, Nooter K, Sparreboom A (2001) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37:1590–1598

    Article  Google Scholar 

  28. Lam YW, Chan CY, Kuhn JG (1997) Pharmacokinetics and pharmacodynamics of the taxanes. J. Oncol. Pharm. Pract 3:76–93

    Article  Google Scholar 

  29. Yang T, Choi MK, Chung SJ, Shim CK, Kim CC (2007) Liposome formulation of paclitaxel with enhanced solubility and stability. Drug Deliv 5:3

    Google Scholar 

  30. Sharma A, Mayhew E, Bolcsak L, Cavanaugh C, Harmon P, Janoff A, Bernacki RJ (1997) Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int. J. Cancer 71:103–107

    Article  Google Scholar 

  31. Fetterly GJ, Straubinger RM (2003) Pharmacokinetics of paclitaxel-containing liposomes in rats. Am Assoc Pharm Sci 5(4):90–100

    Google Scholar 

  32. Kunstfeld R, Wickenhauser G, Michaelis U, Teifel M, Umek W, Naujoks K, Wolff K, Petzelbauer P (2003) Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a “humanized” SCID mouse model. J Invest Dermat 120:476–482

    Article  Google Scholar 

  33. Koudelka S, Turánek J (2012) Liposomal paclitaxel formulations. J Control Release 163:322–334

    Article  Google Scholar 

  34. Wang H, Cheng G, Du Y, Ye L, Chen W, Zhang L, Wang T, Tian J, Fu F (2013) Hypersensitivity reaction studies of a polyethoxylated castor oil-free, liposome-based alternative paclitaxel formulation. Mol Med Rep 7:947–952

    Article  Google Scholar 

  35. Bernabeu E, Cagel M, Lagomarsino E, Moretton M, Chiappetta DA (2017) Paclitaxel: what has been done and the challenges remain ahead. Int J Pharm 526:474–495

    Article  Google Scholar 

  36. Najlah M, Jain M, Wan KW, Ahmed W, Albed Alhnan M, Phoenix DA, Taylor KM, Elhissi A (2016) Ethanol-based proliposome delivery systems of paclitaxel for in vitro application against brain cancer cells. J Liposome Res:1–12. https://doi.org/10.1080/08982104.2016.1259628

  37. Musumeci T, Vicari L, Ventura CA, Gulisano M, Pignatello R, Puglisi G (2006) Lyoprotected nanosphere formulations for paclitaxel controlled delivery. J Nanosci Nanotechnol 6:1–8

    Article  Google Scholar 

  38. Ahmad N, Alam MA, Ahmad R, Naqvi AA, Ahmad FJ (2017) Preparation and characterization of surface-modified PLGA-polymeric nanoparticles used to target treatment of intestinal cancer. Artif Cells Nanomed Biotechnol 1-14. doi:https://doi.org/10.1080/21691401.2017.1324466

  39. Fonseca C, Simo’es S, Gaspar R (2002) Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release 83:273–286

    Article  Google Scholar 

  40. Xu Z, Gu W, Huang J, Sui H, Zhou Z, Yang Y, Yan Z, Li Y (2005) In vitro and in vivo evaluation of actively targetable nanoparticles for paclitaxel delivery. Int J Pharm 288:361–368

    Article  Google Scholar 

  41. Zhigaltsev IV, Winters G, Srinivasulu M, Crawford J, Wong M, Amankwa L, Waterhouse D, Masin D, Webb M, Harasym N, Heller L, Bally MB, Ciufolini MA, Cullis PR, Maurer N (2010) Developement of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles. J Control Release 144:332–340

    Article  Google Scholar 

  42. Desai N, Yao Z, Soon-Shiong P, Dykes D (2002) Evidence of enhanced in vivo efficacy at maximum tolerated dose (MTD) of nanoparticle paclitaxel (ABI-007) and taxol in 5 human tumor xenografts of varying sensitivity to paclitaxel. Am Soc Clin Oncol 21:462

    Google Scholar 

  43. Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Richard L, Rivera ET, Esmaeli B, Ring ES, Bedikian A, Hortobagyi NG, Ellerhorst AJ (2002) Phase I and pharmacokinetic study of ABI-007, a cremophor-free protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8:1038–1044

    Google Scholar 

  44. Ibrahim NK, Samuels B, Page R, Doval D, Patel MK, Rao CS, Nair KM, Bhar P, Desai N, Hortobagyi GN (2005) Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 23(25):6019–6026

    Article  Google Scholar 

  45. O’Shaughnessy J, Tjulandin S, Davidson N, Shaw H, Desai N, Hawkins MJ (2003) ABI-007 (ABRAXANE™), a nanoparticle albumin-bound (nab) paclitaxel demonstrates superior efficacy vs taxol in MBC: a phase III trial. Proceedings from the 26th annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA

    Google Scholar 

  46. Green MR, Manikhas GM, Orlov S, Afanasyev B, Makhson AM, Bhar P, Hawkins MJ (2006) Abraxane, a novel cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 17:1263–1268

    Article  Google Scholar 

  47. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O’Shaughnessy J (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23(31):7794–7803

    Article  Google Scholar 

  48. Garber K (2004) Improved paclitaxel formulation—hints at new chemotherapy approach. J Natl Cancer Inst 96:90–91

    Article  Google Scholar 

  49. Blair HA, Deeks ED (2015) Albumin-bound paclitaxel: a review in non-small cell lung cancer. Drugs 75:2017–2024

    Article  Google Scholar 

  50. Kim T-Y, Kim D-W, Chung J-Y, Shin SG, Kim S-C, Heo SD, Kim KN, Bang Y-J (2004) Phase I and pharmacokinetic study of genexol-pm, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 10:3708–3716

    Article  Google Scholar 

  51. Lee SW, Kim YM, Cho CH, Kim YT, Kim SM, Hur SY, Kim JH, Kim BG, Kim SC, Ryu HS, Kang SB (2017) An open-label, randomized, parallel, phase II trial to evaluate the efficacy and safety of a cremophor-free polymeric micelle formulation of paclitaxel as first-line treatment for ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG-3021). Cancer Res Treat. In Press Cancer Res Treat. doi: 10.4143/crt.2016.376

  52. Kim D-W, Kim S-Y, Kim H-K, Kim S-W, Shin S-W, Kim SJ, Park K, Lee YM, Heo SD (2007) Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. European Society for Medical Oncology 18:2009–2014

    Article  Google Scholar 

  53. Najlah M, D’Emanuele A (2006) Crossing cellular barriers using dendrimer nanotechnologies. Curr Opin Pharmacol 6:522–527

    Article  Google Scholar 

  54. Ooya T, Lee J, Park K (2003) Effects of ethylene glycol-based graft, star-shaped, and dendritic polymers on solubilization and controlled release of paclitaxel. J Control Release 93:121–127

    Article  Google Scholar 

  55. Kan P, Chen ZB, Lee CJ, Chu IM (1999) Development of nonionic surfactant/phospholipid o/w emulsion as a paclitaxel delivery system. J Control Release 58:271–278

    Article  Google Scholar 

  56. Najlah M, Kadam A, Wan KW, Ahmed W, Taylor KM, Elhissi AM (2016) Novel paclitaxel formulations solubilized by parenteral nutrition nanoemulsions for application against glioma cell lines. Int J Pharm 506:102–109

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. College of Pharmacy, Qatar University, Doha, Qatar

    A. Elhissi

  2. School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston, PR1 2HE, UK

    R. Mahmood, I. Parveen & A. Vali

  3. School of Mathematics and Physics, University of Lincoln, Lincoln, LN6 7TS, UK

    W. Ahmed

  4. School of Interdisciplinary Studies, Kansas State University, Manhattan, KS, 66506, USA

    M. J. Jackson

Authors
  1. A. Elhissi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Mahmood
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. Parveen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Vali
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W. Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. J. Jackson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Elhissi .

Editor information

Editors and Affiliations

  1. School of Interdisciplinary Studies, Kansas State University, Manhattan, Kansas, USA

    Mark J. Jackson

  2. School of Mathematics and Physics, University of Lincoln, Lincoln, United Kingdom

    Waqar Ahmed

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Elhissi, A., Mahmood, R., Parveen, I., Vali, A., Ahmed, W., Jackson, M.J. (2018). Taxane Formulations: From Plant to Clinic. In: Jackson, M., Ahmed, W. (eds) Micro and Nanomanufacturing Volume II. Springer, Cham. https://doi.org/10.1007/978-3-319-67132-1_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-67132-1_2

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-67130-7

  • Online ISBN: 978-3-319-67132-1

  • eBook Packages: EngineeringEngineering (R0)

Publish with us

Policies and ethics

Search

Navigation